Determination of 6258-70, a new semi-synthetic taxane, in rat plasma and tissues: Application to the pharmacokinetics and tissue distribution study  by Zhao, Simin et al.
Journal of Pharmaceutical Analysis 6 (2016) 219–225H O S T E D  B Y Contents lists available at ScienceDirectjournal homepage: www.elsevier.com/locate/jpa





E-mwww.sciencedirect.comOriginal ArticleDetermination of 6258-70, a new semi-synthetic taxane, in rat plasma and
tissues: Application to the pharmacokinetics and tissue distribution study$
Simin Zhao, Yuanyuan Zhang, Ping Ju, Liqiang Gu, Rui Zhuang, Longshan Zhao, Xing Tang,
Kaishun Bi, Xiaohui Chen n
School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016, Chinaa r t i c l e i n f o
Article history:
Received 10 October 2015
Received in revised form
27 December 2015
Accepted 29 February 2016






79/& 2016 Xi'an Jiaotong University. Producti
reativecommons.org/licenses/by-nc-nd/4.0/).
review under responsibility of Xi′an Jiaotong
esponding author.
ail address: cxh_syphu@hotmail.com (X. Chena b s t r a c t
Cancer is the leading cause of death all over the world. Among the chemotherapy drugs, taxanes play an
important role in cancer treatment. 6258-70 is a new semi-synthetic taxane which has a broad spectrum
of antitumor activity. A fast and reliable high performance liquid chromatography-tandem mass spec-
trometry (HPLC–MS/MS) method was developed for quantiﬁcation of 6258-70 in rat plasma and tissues
in this paper. After extraction by liquid-liquid extraction method with methyl tert-butyl ether, the
samples were separated on a Kinetex C18 column (50 mm2.1 mm, 2.6 mm, Phenomenex, USA) within
3 min. The method was fully validated with the matrix effect between 87.7% and 99.5% and the recovery
ranging from 80.3% to 90.1%. The intra- and inter-day precisions were less than 9.5% and the accuracy
ranged from 3.8% to 6.5%. The reliable method was successfully applied to the pharmacokinetics and
tissue distribution studies of 6258-70 after intravenous administration in rats. The pharmacokinetic
results indicated that the pharmacokinetic behavior of 6258-70 in rats was in accordance with linear
features within tested dosage of 1 to 4 mg/kg, and there was no signiﬁcant difference between the two
genders. The tissue distribution study showed that 6258-70 had an effective penetration, spread widely
and rapidly and could cross blood-brain barrier. The results of pharmacokinetics and tissue distribution
may provide a guide for future study.
& 2016 Xi'an Jiaotong University. Production and hosting by Elsevier B.V. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The incidence of cancer is increasing, and cancer is becoming
the leading cause of death all over the world [1,2]. Plenty of cancer
chemotherapy drugs were adopted while taxanes were the most
popular and active ones in the last two decades. Taxanes are po-
tent microtubule poisons that promote microtubule to assemble
and prevent its depolymerization, which is essential for mitotic
function of cancer cell [35]. Among these taxanes, paclitaxel and
docetaxel are the most widely used drugs as the front-line treat-
ment or combination drugs for the therapy of ovarian cancer,
breast cancer, non-small cell lung cancer and cervical cancer [6].
However, the long-term use of taxanes is limited contributed to
two major reasons. First, as taxanes have high substrate afﬁnity
for multidrug-resistance (MDR) proteins, in particular the ATP-
dependent drug efﬂux pump P-glycoprotein (P-gp), it can lead to
MDR reaction. In addition, because of poor solubility of taxanes,
Tween 80 and Cromoplor EL need to be used, which can causeon and hosting by Elsevier B.V. Th
University.
).hypersensitivity reactions and cumulative ﬂuid retention [7-9].
According to the study of structure-activity relationship, the active
compound which is derived from taxanes by modifying C-2, C-10
and C-3′ position shows a great improvement towards MDR and
keeps the same activity at the same time [10-12]. These derivative
compounds from taxanes include cabazitaxel, larotaxel, and tese-
taxel, which are under clinical test [13–16]. Thus, it is very
meaningful to modify structure of taxanes in order to obtain new
drugs with lower toxicity and higher effect, especially against the
drug-resistant human cancer.
6258-70 (Fig. 1A) is a new semi-synthetic taxane derivatived
with modiﬁcation at the C-7, C-10 and C-3′ position from
docetaxel (DTX) (Fig. 1B). As one member of taxanes, 6258-70 has
the same advantages as other taxanes, including good active and
broad spectrum of antitumor activity. In addition, according to the
study on structure-activity relationship [10], as phenyl is replaced
with isobutenyl at C-3′ position, 6258-70 shows poorer afﬁnity to
P-gp compared with docetaxel. These advantages make 6258-70
meaningful for deeper research.
According to ICH S9 Nonclinical Evaluation for Anticancer
Pharmaceuticals [17], preclinical pharmacokinetic study plays an
important role in the development of new drugs. The pharmaco-
kinetic parameters in animal species can be used to make criticalis is an open access article under the CC BY-NC-ND license
Fig. 1. Chemical structures and full scan mass spectra of (A) 6258-70 and
(B) docetaxel.
Table 1
Calibration curves of 6258-70 in rat plasma and tissue homogenate.
Samples Slope102 Intercept102 R Linear ranges (ng/mL)
Plasma 1.24 0.87 0.999 44000
Liver 1.18 0.43 0.997 44000
Heart 1.08 0.52 0.998 44000
Spleen 0.72 3.94 0.997 44000
Lung 0.93 5.11 0.993 44000
Kidney 0.98 3.93 0.994 44000
Intestine 1.19 1.94 0.992 44000
Stomach 1.07 3.51 0.996 44000
Muscle 1.11 0.60 0.997 44000
Bladder 1.05 2.34 0.998 44000
Brain 0.92 4.52 0.999 44000
Fat 1.66 0.84 0.999 44000
Pancreas 1.23 0.76 0.996 44000
Testicle 0.83 1.51 0.997 44000
Uterus 0.86 0.42 0.997 44000
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reliable analytical methods for the quantitative evaluation of a
drug are critical for the conduct of preclinical, biopharmaceutics
and clinical pharmacology research. However, as far as we know,
there have been no reports on the pharmacokinetics and tissue
distribution studies of 6258-70. Thus, a fast and reliable high
performance liquid chromatography–tandem mass spectrometry
(HPLC–MS/MS) bioanalytical method was developed and suc-
cessfully applied to the quantiﬁcation of 6258-70 in rat plasma and
tissues for the ﬁrst time in this paper. The pharmacokinetics andFig. 2. MRM chromatograms of blank rat matrix (plasma or liver homogenate), blank
homogenate at 12 h.tissue distribution properties of 6258-70 after injection were de-
monstrated and discussed in this work, which will be useful for
future studies.2. Experimental
2.1. Chemical reagents and animals
6258-70 (purity 498.0%), docetaxel (DTX, purity 498%) (IS)
and 6258-70 injection were supplied by Professor Xing Tang from
Shenyang Pharmaceutical University. Acetonitrile, methanol and
ammonium acetate of HPLC grade were purchased from Fisher
Scientiﬁc (Fair Lawn, NJ, USA). Distilled water was provided by
Wahaha Co., Ltd. (Hangzhou, China) and used throughout the
study. Other chemical reagents were of analytical grade.
Sprague-Dawley (SD) rats (mean weight 220710 g) wererat matrix spiked with 6258-70 and IS, and rat plasma sample at 10 h or liver
Table 2
Precision, accuracy, recovery and matrix effect of HPLC–MS/MS method for analysis of 6258-70 and IS in rat plasma and liver (n¼6).








Intra-day (RSD, %) Inter-day (RSD, %)
Plasma 6258-70 10 2.2 9.4 9.5 93.879.1 84.377.3
200 3.2 8.7 9.3 89.974.8 90.1711.1
3200 0.1 6.9 6.8 99.574.7 88.075.1
DTX 5000 – – – 98.177.1 80.375.8
Liver 6258-70 10 3.2 3.0 4.2 90.071.3 88.075.1
200 6.5 6.5 3.6 87.772.1 88.576.2
3200 3.8 3.9 4.7 88.273.3 86.474.3
DTX 4000 – – – 96.373.9 85.274.6
Table 3
Stability of the analytes in rat plasma and liver homogenate (n=3).
Type of matrix Concentration (ng/mL) Room temperature for 4 h 80 °C for 30 days Three freeze-thaw cycles 8 h after prepared at 10 °C
RE (%) RSD (%) RE (%) RSD (%) RE (%) RSD (%) RE (%) RSD (%)
Plasma 10 8.7 5.2 3.9 7.6 8.5 5.9 8.1 5.1
200 1.8 14.1 5.6 6.8 2.7 14.5 9.9 5.2
3200 4.5 2.0 1.0 9.7 5.7 8.1 3.2 5.9
Liver 10 2.8 4.1 11.3 1.3 14.4 3.2 2.7 8.8
200 7.5 14.0 7.9 1.1 3.8 2.2 4.9 3.0
3200 5.6 9.7 4.9 3.9 6.3 3.2 3.3 8.5
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Pharmaceutical University (Shengyang, China). All procedures for
animals were in accordance with the Guideline for Animal Ex-
perimentation of Shenyang Pharmaceutical University and the
Regulations of Experimental Animal Administration issued by the
State Committee of Science and Technology of People’s Republic of
China.
2.2. HPLC–MS/MS conditions
An ACQUITY Ultra-Performance Liquid Chromatography system
(Waters Corp., Milford, MA, USA) equipped with a Xevo-TQ mass
spectrometer (Waters Corp., Milford, MA, USA) with an electro-
spray ionization (ESI) interface and triple quadruple mass analyzer
was applied to the assay.
Chromatographic separation was accomplished on a Kinetex
C18 column (50 mm2.1 mm, 2.6 mm, Phenomenex, USA)
within 3 min. Gradient elution was applied with mobile phase A
(acetonitrile) and phase B (5 mM ammonium acetate in water) at a
ﬂow rate of 0.2 mL/min. After an injection of 5 μL, phase A was
linearly increased from 50% to 95% in 1.0 min, and kept for 1.0 min.
Then, it was decreased to 50% during the following 0.2 min, and
kept for 0.8 min. The column and autosampler tray temperatures
were kept constant at 40 °C and 10 °C, respectively.
Multiple reaction monitoring (MRM) in positive ESI mode was
performed to quantify 6258-70 and IS, respectively. The fragment
transitions for 6258-70 and IS werem/z 906.6-539.4 and 808.5-
527.3, respectively. The cone voltage and collision energy were
20 V and 10 eV for 6258-70, 16 V and 8 eV for IS. Other parameters
are as follows: capillary voltage, 3.0 KV; cone gas (N2), 50 L/h;
desolvation gas (N2), 400 L/h; collision gas (Ar2), 0.18 L/h; source
temperature, 150 °C; desolvation temperature, 400 °C.
2.3. Preparation of stock solutions and calibration standard solutions
Stock solutions of 6258-70 and IS were prepared with metha-
nol, both at a concentration of 0.1 mg/mL. The stock solution of the
analyte was serially diluted to get the working solutions withmethanol. IS working solutions of 5000 ng/mL and 4000 ng/mL
were diluted from the stock solution by methanol. All the solutions
were stored under 20 °C.
Calibration standard samples (4, 10, 25, 100, 400, 1600,
4000 ng/mL) were obtained by adding 20 μL of working solutions
to 50 μL blank rat plasma or 100 μL tissue homogenates, and
quality control (QC) samples (10, 200, 3200 ng/mL) were prepared
in the same way from another stock solution.
2.4. Preparation of 6258-70 injection and sampling
6258-70 injection for rats was prepared by dissolving the
compound in Tween 80 (1:26, m/m), and then diluted with
ethanol-physiological saline (13:87, m/v) to the ﬁnal concentra-
tion. All procedures for animals were in accordance with the
Guideline for Animal Experimentation of Shenyang Pharmaceu-
tical University and the Regulations of Experimental Animal
Administration issued by the State Committee of Science and
Technology of People’s Republic of China.
In the pharmacokinetic study, 36 SD rats (50% of each sex) were
randomly assigned to three groups. After intravenous adminis-
tration with 6258-70 at a single dose of 1, 2 and 4 mg/kg,
respectively, blood samples of 0.2 mL were collected from the
suborbital vein into heparinized tubes at 0.083, 0.17, 0.33, 0.5, 1.0,
1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0 and 12.0 h. An immediate cen-
trifugation at 1520 g was performed for 5 min and about 100 μL of
plasma was obtained. All the plasma samples were stored at
80 °C until determination.
For the tissue distribution study, 24 SD rats (50% of each sex)
were randomly divided into 4 groups (six rats per group). 6258-70
was administered to rats at a dose of 2 mg/kg via intravenous
administration. Liver, heart, spleen, lung, kidney, stomach, intes-
tine, muscle, brain, bladder, testicle, uterus, fat and pancreas were
collected at 0.25, 2, 6, and 12 h after administration, respectively.
Tissue samples were washed in ice-cold 0.9% saline solution and
wiped with ﬁlter paper. After that, all tissues were shredded and
then about 0.33 g of the tissue samples (taking all the tissue
Fig. 3. Mean concentration–time curves of 6258-70 in rat plasma after intravenous
administration at different doses of 1, 2 and 4 mg/kg (n¼6) for (A) male and
(B) female rats.
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was less than 0.33 g) were weighed and homogenized with 1 mL
of methanol, and then the supernatant was stored at 80 °C until
the analysis.
2.5. Sample preparation
An aliquot of 50 μL plasma or 100 μL tissue homogenate was
spiked with 20 μL IS working solution, 20 μL methanol and 100 μL
distilled water. The mixture was extracted with 2 mL methyl tert-
buthl ether by vortex mixing for 3 min. After centrifugation at
1520 g for 5 min, the upper organic layer was transferred to a tube
and evaporated to dryness at 35 °C under nitrogen. The residue
was redissolved in 200 μL methanol, and an aliquot of 5 μL was
injected into the HPLC–MS/MS system.
2.6. Method validation
The method was fully validated in accordance with United
States Food and Drug Administration (US FDA) guidelines and re-
lated reference [18,19]. Selectivity was investigated using six
sources of the appropriate blank matrix (plasma or liver homo-
genate), one spiked sample (lower limit of quantiﬁcation, LLOQ),
and one sample at 10 h (plasma) or 12 h (liver homogenate) after
dosing for monitoring interference of endogenous components in
matrix or metabolites.
For calibration curves, which ranged from 4 to 4000 ng/mL, a
least-squares linear regression with a weighted factor (1/C2) was
adopted to plot the response ratio of 6258-70/IS versus the
nominal concentration. The LLOQ was deﬁned as the concentra-
tion with, at least, a signal-to-noise ratio of 10, and with an
acceptable accuracy within 720% and the precision below 20%.
Intra- and inter-day precision and accuracy were determined
by analyzing QC samples at low, medium and high concentrations
on three different days with six replicates at each concentration
per day. Precision was deﬁned as the relative standard deviation
(RSD%) and accuracy was deﬁned as relative error (RE%).
The recovery of the analyte was determined at three QC levels
with six replicates by comparing the peak areas from extracted
samples with those from extracted blank samples spiked with the
analyte at the same concentration. Matrix effects were calculated
by the peak ratio of blank sample extracts spiked with the analyte
to pure standard solution containing equivalent amounts of the
compounds. The recovery and the matrix effect of IS were de-
termined in the same way at the concentration of 5000 ng/mL for
pharmacokinetics and 4000 ng/mL for tissue distribution.
Stability studies in plasma and liver homogenate were also
conducted at three QC levels under several different storage con-
ditions: at room temperature for 4 h, at 80 °C for 30 days, after
three freeze-thaw cycles, and 8 h after preparation at 10 °C.
The carry-over effect was investigated by injecting a blank
plasma sample after the injection of an upper limit of quantiﬁca-
tion sample (ULQQ), and peak area found in the ﬁrst blank sample
should be less than 20% of the peak area at LLOQ of the analyte.
2.7. Statistical analysis
The pharmacokinetic parameters of 6258-70 were obtained by
the non-compartmental analysis of plasma concentration versus
time proﬁles using the DAS 2.1 software package (Chinese Phar-
macological Society). All the data were expressed as mean
7standard deviation (SD). The pharmacokinetic parameters in the
two gender groups were compared using SPSS software (ver.16.0;
SPSS, Chicago, IL) in independent samples T-test or Mann–Whit-
ney test. When p was less than 0.05, it could be deemed that there
was signiﬁcant difference.3. Results and discussion
3.1. HPLC–MS/MS optimization
The standard solutions of 6258-70 and IS, at the concentration of
1 μg/mL respectively, were infused into the mass spectrometer to
full scan in positive and negative modes. The results showed that
the ion [MþH]þ at m/z 906.6 and 808.5 exhibited the highest io-
nization response for 6258-70 and IS, respectively with most
abundant stable fragment ions of m/z 906.6-539.4 and 808.5-
527.3, respectively. Therefore, 906.6 and 808.5 were selected as
parent ions and 539.4 and 527.3 were chosen as daughter ions.
The composition of mobile phase has a signiﬁcant inﬂuence on
chromatographic behavior and appropriate ionization. Acetonitrile
was chosen as the organic phase for higher responses. The addi-
tion of formic acid was found to increase the response of 6258-70,
while the peak was likely to be bifurcation during the gradient
elution. Compared with formic acid, addition of 5 mM ammonium
acetate in water led to an enhanced response and good peak
Table 4
Main pharmacokinetic parameters of 6258-70 after intravenous administration at three doses for different genders in rats (mean7SD; n¼6).
Parameters Male Female
1 mg/kg 2 mg/kg 4 mg/kg 1 mg/kg 2 mg/kg 4 mg/kg
AUC0t (μg h/L) 149.0735.6 188.2734.3 941.37179.3 109.4726.3 214.9774.6 903.27200.2
AUC01 (μg h/L) 261.4741.0 266.2732.8 1139.07204.8 167.0736.8 270.6794.8 1049.77233.5
t1/2 (h) 8.172.0 8.072.4 7.971.7 7.972.9 6.171.4 7.572.5
Cmax (ng/mL) 66.0713.6 217.7758.6 1358.87230.9 67.6720.6 263.9794.7 1388.47447.9
CLz (L/h/kg ) 3.970.7 7.671.0 3.670.7 6.371.7 8.172.7 4.071.2
Vz (L/kg) 44.979.8 89.1735.6 40.9710.5 68.5722.6 68.1716.1 41.7711.4
MRT0 t (h) 4.470.5 2.870.5 6.071.6 3.570.4 2.870.5 4.970.2
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5 mM ammonium acetate.
3.2. Sample preparation
Although protein precipitation is faster and simpler, the over-
run matrix effect for 6258-70 was unignored. Liquid-liquid ex-
traction was surveyed. Several solvents such as ethyl acetate, ether
and methyl tert-buthyl ether were tested, among which methyl
tert-butyl ether provided a better recovery more than 80%.
Moreover, the addition of 100 μL distilled water was used to get a
cleaner sample with appropriate matrix effect.Fig. 4. Tissue distribution of 6258-70 after intravenous administration for (A) male and (
that there was a signiﬁcant difference of the concentration of drug in tissue between th3.3. Method validation
Typical chromatograms of blank rat matrix (plasma or liver
homogenate), blank rat matrix spiked with 6258-70 and IS, and rat
plasma sample at 0.5 h or liver homogenate at 12 h after admin-
istration are shown in Fig. 2. No interference was observed at re-
tention time of 6258-70 (1.88 min) or the IS (1.33 min). The cali-
bration curves showed good linearity over the concentration
ranging from 4 to 4000 ng/mL for 6258-70. Typical calibration
curves for 6258-70 in rat plasma and different tissues are listed in
Table 1. All the correlation coefﬁcients (R) were Z0.99. The LLOQ
of the assay was 4 ng/mL in rat plasma and liver homogenates,B) female rats at dose of 2 mg/kg. n means po0.05 and nn means po0.01, indicating
e two genders.
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5.2% in liver. Intra- and inter-day precision, accuracy and recovery
for the analyte and IS are summarized in Table 2. The matrix effect
of 6258-70 and IS in spiked rat plasma and liver homogenate was
between 87.7% and 99.5%, indicating that no signiﬁcant matrix
effect was observed for 6258-70 or IS. All standards met the cri-
teria of o15% deviation from nominal concentration. The results
of the stability tests are listed in Table 3. The analyte and IS were
found to be stable in the plasma samples and liver samples at
room temperature for 4 h, at 80 °C for 30 days, after three
freeze-thaw cycles, and 8 h after prepared at 10 °C. No peak area
more than 20% of the lowest calibrator was detected in the blank
sample injected after ULOQ, resulting in a negligible carry-over
effect. These results show the method is reliable enough.
3.4. Pharmacokinetic study and tissue distribution
The validated method was successfully applied to the phar-
macokinetic study of 6258-70 at three different doses after in-
travenous administration. The mean plasma concentration vs time
curves of 6258-70 between female and male at three doses are
shown in Fig. 3, while related pharmacokinetic parameters are
listed in Table 4. The linear regression analysis about experimental
data showed priority to the lnAUC0t and dosage, lnAUC01 and
dosage, as well as lnCmax and dosage between female and male
rats, and the coefﬁcient (R2) were above 0.86. This result demon-
strated that the pharmacokinetic behavior of 6258-70 in vivo was
in accordance with linear features within tested dosage. Pharma-
cokinetic parameters of two gender groups at three dosages after
intravenous administration, AUC0t, AUC01, Cmax, Vz and CLz,
were compared via an independent-samples T-test after logarith-
mic transformation. t1/2 and MRT0t were measured using Mann-
Whitney test. With statistical analysis, the results indicated that
dosage did not affect the pharmacokinetic parameters (p40.05) of
6258-70 between two genders at three dosages. These pharma-
cokinetic properties may afford some references to dosing region
of future toxicity and toxicokinetic test.
The tissue distribution of 6258-70 at 2 mg/kg after intravenous
administration are presented in Fig. 4. The results indicated that
6258-70 distributed widely and rapidly, having an effective pe-
netration and wider spectrum of antitumor active. As Fig. 4 pre-
sents, the content of 6258-70 was higher in rich-blood tissues,
such as heart, liver, spleen, lung and kidney. In addition, 6258-70
could also be observed in the brain, uterus, gastrointestinal tract
and pancreas. The amount of the drug across the blood-brain-
barrier (BBB) depends on the lipophilicity and molecular weight
[20]. 6258-70 with highly lipophilic property can easily transport
across brain endothelial cells by passive diffusion. Meanwhile,
there was some 6258-70 in gastrointestinal tract and pancreas,
which may have an effect on patients’ life quality. It may be taken
into consideration when we choose prescription design and
formulation.
As regard to gender differences, the concentration of 6258-70
in collected tissues at measured time between two genders was
analyzed via an independent-samples T-test after logarithmic
transformation, and results are listed in Fig. 4. The results in-
dicated there were signiﬁcant differences at different time in some
collected tissues, including liver, spleen, lung, kidney, intestine and
pancreas, especially in reproductive organs, which maybe related
to the differences in fat, weight, enzymes, as well as hormone. In
addition, as taxanes are metabolized by CYP3A, it is possible for
6258-70 metabolized in this way, while the active and content of
CYP3A are different between two genders [21–26].
There are some researches on derivative compounds from
taxanes, such as DTX, TM-2 and Larotaxel [27–29]. Compared with
DTX, 6258-70 has a longer t1/2 and a higher CLz [20].Pharmacokinetic behavior of TM-2 and 6258-70 in vivo was in
accordance with linear features within tested dosage and they
have the similar t1/2. Compared with Larotaxel, 6258-70 has a
longer t1/2. Besides, both 6258-70 and Larotaxel are distributed
widely and rapidly. The content of 6258-70 and Larotaxel was
higher in rich-blood tissues, such as heart, liver, spleen, lung and
kidney, and could also be observed in the BBB.4. Conclusions
It is the ﬁrst time of developing a method for quantiﬁcation of
6258-70, a new semi-synthetic taxane, in rat plasma and tissues.
The fully validated method was successfully applied to the phar-
macokinetics and tissue distribution studies of the two genders.
The pharmacokinetic results indicated that the pharmacokinetic
behavior of 6258-70 in rats was in accordance with linear features
within tested dosage and there was no signiﬁcant difference be-
tween two genders. The tissue distribution study showed 6258-70
had an effective penetration, spreading widely and rapidly. In
addition, 6258-70 accumulated most in rich-blood tissues and
could cross BBB. Besides, there are some differences in liver,
spleen, lung, intestine, pancreas, fat and reproductive organs be-
tween the two genders. Thus, it may need more attention to this
question in future study. The method and results of pharmacoki-
netics and tissue distribution in this paper may be useful to further
study of 6258-70.References
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